Related Experiment Video
Updated: Dec 13, 2025
10:35
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
3.1K
PolyMet-HA nanocomplexs regulates glucose uptake by inhibiting SHIP2 activity
Xinlu Yuan1, Ling Ding1, Jianjun Diao1
1542170Fudan University Pudong Medical Center, Shanghai Pudong Hospital, Shanghai, China.
Journal of Biomaterials Applications
|August 4, 2020
Summary
Researchers developed PolyMetformin-hyaluronic acid (HA) nanocomplexes to improve type 2 diabetes treatment. These novel nanocomplexes enhance glucose uptake and may offer an alternative to metformin with fewer side effects.
Area of Science:
- Biomaterials Science
- Pharmacology
- Cell Biology
Background:
- Metformin is a first-line type 2 diabetes drug that inhibits liver gluconeogenesis.
- Metformin's adverse effects include lactic acidosis and gastrointestinal issues, necessitating improved therapies.
- Developing treatments with enhanced permeability and retention is crucial for effective diabetes management.
Purpose of the Study:
- To synthesize and characterize biocompatible PolyMetformin-hyaluronic acid (HA) nanocomplexes.
- To evaluate the efficacy of PolyMet-HA nanocomplexes in regulating glucose uptake and cellular signaling pathways.
- To explore the potential of PolyMet-HA nanocomplexes as an alternative treatment for type 2 diabetes.
Main Methods:
- PolyMetformin (PolyMet) was synthesized by conjugating PEI1.8K with dicyandiamide.
- PolyMet-HA nanocomplexes were formed via electrostatic self-assembly.
- In vitro assays assessed SHIP2 phosphatase activity, glucose uptake in myotubes, Akt signaling restoration, and podocyte apoptosis.
Main Results:
- PolyMet-HA nanocomplexes reduced SHIP2 phosphatase activity in vitro, similar to metformin.
- These nanocomplexes improved glucose uptake in SHIP2-overexpressing myotubes by downregulating glucose transporter 4 endocytosis.
- PolyMet-HA nanocomplexes restored Akt signaling and protected podocytes from apoptosis.
Conclusions:
- PolyMet-HA nanocomplexes exhibit metformin-like activity in enhancing glucose uptake.
- The developed nanocomplexes show potential for treating type 2 diabetes with potentially improved pharmacokinetic properties.
- Further research into PolyMet-HA nanocomplexes could lead to novel therapeutic strategies for diabetes management.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
437
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
437
01:06Oral Hypoglycemic Agents: Glinides
478
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
478
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
507
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
507
01:26Glucose Absorption Into the Small Intestine
34.2K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.2K
01:16Hormones Regulating Blood Glucose
6.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.0K
01:23Dipeptidyl Peptidase 4 Inhibitors
446
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
446